Mark Suseck
About Mark Suseck
Mark Suseck, 62, is Chief Operating Officer of Impact BioMedical Inc. (IBO) since August 2023. He holds a B.A. in Economics from Rutgers University with minors in Education and Philosophy, and completed the Executive Management Program in residence at the University of Michigan Business School . Company EBITDA improved year-over-year (FY 2023 to FY 2024), providing operational context during his tenure as COO*.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| DSS BioHealth Holdings Inc. (subsidiary of DSS, Inc.) | Chief Operating Officer | 2020–2023 | Led company strategy, operations, licensing, acquisitions, and commercialization . |
| Vivacitas Oncology Inc. | Chief Executive Officer | 2021–2022 | Led strategy, clinical development, operations, and financing . |
| Helius Medical Technologies Inc. | VP, Global Sales & Marketing | 2018–2019 | Led global sales and marketing . |
External Roles
No public company directorships or external board roles for Mr. Suseck are disclosed .
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | $0 | $126,689 |
| Target Bonus (%) | Not disclosed | Not disclosed |
| Actual Bonus Paid ($) | $0 | $0 |
| Stock Awards ($) | $0 | $32,000 |
| Option Awards ($) | $0 | $0 |
- Employment Agreement sets base salary at $250,000, retroactive to April 1, 2024; discretionary bonus eligible (cash or common stock) .
Performance Compensation
| Incentive Type | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Discretionary Bonus | Board discretion (no stated financial metrics) | N/A | Not disclosed | Not disclosed | Not disclosed | N/A |
| Stock Options | Service-based vesting (various; specific schedule not disclosed) | N/A | 400,000 options; $3.00 strike | Granted | N/A | Various vesting; expires Oct 31, 2031 |
- 2023 Equity Incentive Plan: 880,000 options at $3.00 were granted across officers/directors/consultants for FY 2024; options fair-valued at ~$50,000; SB compensation expense ~$19,000; all expire Oct 31, 2031; vesting periods vary .
- No PSU/TSR/financial metric weighting framework is disclosed for Mr. Suseck .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Total Beneficial Ownership (Common) | 0 shares; <1% of outstanding |
| Ownership as % of Common Outstanding | <1% |
| Vested vs Unvested Shares | Not disclosed |
| Options (Exercisable vs Unexercisable) | 400,000 options granted at $3.00 (exercisability schedule not disclosed) |
| Shares Pledged as Collateral | Not disclosed |
| Stock Ownership Guidelines | Not disclosed |
Employment Terms
| Provision | Terms |
|---|---|
| Role & Start Date | COO since August 2023 |
| Employment Agreement Term | Through September 16, 2027 |
| Base Salary | $250,000, retroactive to April 1, 2024 |
| Bonus | Discretionary; payable in cash or common stock (no target %) |
| Options | 400,000 at $3.00 per share under 2023 Equity Plan |
| Severance | Not disclosed |
| Change-of-Control | Not disclosed |
| Non-Compete/Non-Solicit | Not disclosed |
| Clawback | Not disclosed |
Performance & Track Record (Company Context)
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| EBITDA ($USD) | -$4,022,000* | -$3,390,000* |
Values retrieved from S&P Global.
Governance & Say‑on‑Pay
- Compensation oversight by Compensation Committee: Dr. Elise Brownell (Chair), Melissa Sims, Castel Hibbert .
- 2025 Annual Meeting say‑on‑pay approved: For 61,512,770; Against 107,684; Abstain 4,795; Broker non‑votes 2,702,761 .
- Beneficial ownership concentrated: DSS BioHealth Securities, Inc. (wholly owned by DSS, Inc.) holds ~83.35% voting power via Series A Preferred (60,496,041 shares, 100% of preferred outstanding) .
Investment Implications
- Pay-for-performance alignment: Bonus is discretionary with no disclosed financial/TSR metrics, and equity is option‑based without published performance conditions—reducing transparent alignment to measurable outcomes .
- Ownership alignment: Mr. Suseck holds no common shares (<1%), with alignment primarily via options at $3.00 strike; actual exercisability/vesting schedule is not disclosed, limiting visibility into near‑term selling pressure or retention hooks .
- Retention risk: Employment term runs through 2027, but severance/CIC protections are not disclosed; lack of disclosed protections or long‑dated RSU/PSU structures may imply fewer retention frictions, depending on undisclosed agreement terms .
- Trading signals: Option grants concentrated at $3.00 strike could create sensitivity around equity‑linked milestones; absence of disclosed performance metrics for bonus/awards and low personal share ownership reduce clarity on incentive directionality .
- Governance overlay: With say‑on‑pay approval and a controlling shareholder (via preferred), compensation changes may be stable; however, discretionary constructs and limited disclosure on severance/CIC merit monitoring for future filings .